Back to News
Market Impact: 0.12
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
New analysis of ADAS-Cog data from the company’s randomized, sham-controlled trial reports specific cognitive-domain improvements tied to memory in Alzheimer’s patients, building on earlier publications in the Journal of Alzheimer’s Disease and Radiology. The update is supportive of clinical signals but provides no quantified effect sizes in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- Craneware shares plunge 23% after cyber incident, weaker outlook
- Accenture shares jump 6% in Ipremarket trade after Anthropic AI deal
- Volkswagen, Porsche shares extend losses following profit warning
- Salesforce wants to charge for AI outcomes, but first it needs to figure out how